Healthcare Services

Dermatomycoses Market Size Outlook and Demand Growth Across 2026–2030

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Dermatomycoses Market Over The Period 2026–2030?

The dermatomycoses market has experienced significant expansion in recent years. This market is projected to increase from $14.81 billion in 2025 to $15.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be linked to factors such as exposure to humid climates, inadequate hygiene practices, a dependence on topical medications, insufficient awareness, and the commonality of hospital-based treatments.

The dermatomycoses market is projected to undergo significant expansion over the next few years. It is expected to reach a valuation of $19.11 billion by 2030, advancing at a compound annual growth rate (CAGR) of 5.2%. This growth during the forecast period is attributable to enhancements in antifungal formulations, an increasing frequency of skin infections, the proliferation of outpatient care facilities, heightened awareness about hygiene, and the expansion of dermatology services. Dominant trends anticipated in this period include the rising occurrence of fungal skin infections, a greater adoption of topical antifungals, the evolution of combination antifungal therapies, the broadening of outpatient dermatology care, and a focus on preventing disease recurrence.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp

What Underlying Factors Are Accelerating The Growth Of The Dermatomycoses Market?

The expansion of the aging population is anticipated to stimulate the dermatomycoses market in the future. An aging population signifies a rising count and proportion of individuals aged 65 and above within a country’s demographic framework. This demographic shift is fueled by the large baby boomer generation reaching retirement age, resulting in a greater share of elderly people in society. An increasing number of older individuals contributes to a higher occurrence of fungal skin infections, as the elderly frequently exhibit compromised immune systems, diminished skin barrier function, and other age-related physiological changes that heighten their vulnerability to dermatomycoses such as athlete’s foot, ringworm, and nail infections. For example, data from July 2024, provided by the UK Parliament’s House of Commons Library, a UK-based government administration, showed that in 2022, the UK had 12.7 million people aged 65 or older, representing 19% of the total population. This figure is projected to rise to 22.1 million, or 27% of the population, by 2072. Consequently, the expanding aging population is a key driver for the growth of the dermatomycoses market.

How Is The Dermatomycoses Market Divided Into Its Major Segments?

The dermatomycoses market covered in this report is segmented –

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs

2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administrations

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus

3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide

4) By Immunomodulator: Interferon-Gamma, Thalidomide

5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals

6) By Other Drugs: Antihistamines, Antibacterial Agents

What Key Trends Are Influencing The Development Of The Dermatomycoses Market?

Leading companies in the dermatomycoses market are focusing on investigational new drug candidates to improve the treatment of onychomycosis and enhance its effectiveness. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical evaluation to assess its safety, efficacy, and potential for regulatory approval before becoming an approved therapy. For example, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its investigational new drug candidate, VTR-297, for the treatment of onychomycosis. VTR-297 is a topical antifungal candidate distinguished by its unique histone deacetylase (HDAC) inhibitor properties, setting it apart from traditional antifungal treatments. Its mechanism targets the underlying cause of fungal growth and demonstrates strong antifungal activity against dermatophytes and other fungal species. This innovative approach has the potential to deliver faster and more effective treatment outcomes while reducing the likelihood of recurrence, addressing a significant unmet need in onychomycosis treatment.

Who Are The Prominent Organizations Shaping The Dermatomycoses Market?

Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

Read the full dermatomycoses market report here:

https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

Which Region Is Projected To Dominate The Dermatomycoses Market During The Forecast Period?

North America was the largest region in the dermatomycoses market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Dermatomycoses Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21934&type=smp

Browse Through More Reports Similar to the Global Dermatomycoses Market 2026, By The Business Research Company

Dermatitis Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Veterinary Dermatology Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-dermatology-drugs-global-market-report

Onychomycosis Global Market Report

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795